文献速递糖尿病

连续血糖监测在儿童症状前1型糖尿病分期中的区分度与精确性

Discrimination and Precision of Continuous Glucose Monitoring in Staging Children With Presymptomatic Type 1 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在德国巴伐利亚州参加胰岛自身抗体公共卫生筛查的儿童和青少年中,118人接受Dexcom G6连续血糖监测(CGM),97人获得有效数据(57名女性,中位年龄10岁,范围3-17岁),包括46例1期、18例2期和33例无胰岛自身抗体者。研究评估CGM区分抗体阴性对照与早期1型糖尿病的能力,并探索CGM分类指标能否预测进展为临床糖尿病。结果表明CGM有潜力整合入早期1型糖尿病的分期和监测,但其精确性需大幅提高才能用于常规监测实践。

要点

  • 抗体阴性对照的平均血糖中位数为115.3 mg/dL,且变异较大(四分位距106.8-124.4)。
  • 以对照100%特异性的阈值,血糖标准差、TA140、TA160和TA180可区分对照与1期、2期。
  • 上述参数中任意2项升高可识别67%的2期患者和82%的1年内进展为临床糖尿病者。

核心结论

  • 本研究显示CGM有潜力整合入早期1型糖尿病的分期和监测,但其精确性需大幅提高才能用于常规监测实践。

研究设计与样本

  • 研究邀请德国巴伐利亚州参加胰岛自身抗体公共卫生筛查的儿童和青少年接受Dexcom G6连续血糖监测,共118人参与,97人获得有效数据(57名女性,中位年龄10岁,范围3-17岁),包括46例1期、18例2期和33例无胰岛自身抗体者。

主要发现

  • 抗体阴性对照的CGM平均血糖中位数为115.3 mg/dL,四分位距106.8-124.4。
  • 33例对照中11例(33%)有超过10%的血糖值高于140 mg/dL(TA140)。
  • 以对照100%特异性的阈值,血糖标准差、TA140、TA160和TA180在对照与1期、2期之间获得差异。
  • 上述参数中任意2项升高识别了12例(67%)2期患者和11例中9例(82%)在1年内进展为临床糖尿病者。
  • 所有参数组内变异明显,18人第二次CGM的一致性差。

局限性

  • 所有参数组内变异明显,18人第二次CGM的一致性差。
  • CGM精确性需大幅提高才能用于常规监测实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Staging and monitoring of presymptomatic type 1 diabetes includes the assessment for dysglycemia. OBJECTIVE: To assess the ability of continuous glucose monitoring (CGM) to differentiate between islet autoantibody-negative controls and early-stage type 1 diabetes and explore whether CGM classifiers predict progression to clinical diabetes. RESEARCH DESIGN AND METHODS: Children and adolescents participating in public health screening for islet autoantibodies in Bavaria, Germany, were invited to undergo CGM with Dexcom G6. In total, 118 participated and valid data was obtained from 97 [57 female; median age 10 (range 3-17) years], including 46 with stage 1, 18 with stage 2, and 33 with no islet autoantibodies. RESULTS: Mean glucose during CGM in islet autoantibody-negative controls was high (median, 115.3 mg/dL) and varied substantially (interquartile range, 106.8-124.4). Eleven (33%) of the controls had more than 10% of glucose values above 140 mg/dL (TA140). Using thresholds corresponding to 100% specificity in controls, differences between controls and stage 1 and stage 2 were obtained for glucose SD, TA140, TA160, and TA180. Elevations in any 2 of these parameters identified 12 (67%) with stage 2 and 9 (82%) of 11 participants who developed clinical diabetes within 1 year. However, there was marked variation within groups for all parameters and poor consistency observed in a second CGM performed in 18 participants. CONCLUSION: This study demonstrated the potential of integrating CGM into staging and monitoring of early-stage type 1 diabetes. However, substantial improvement in the precision of CGM is required for its application in routine monitoring practices.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Huber E, Singh T, Bunk M, et al. Discrimination and Precision of Continuous Glucose Monitoring in Staging Children With Presymptomatic Type 1 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 39413240. doi:10.1210/clinem/dgae691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。